Acute Coronary syndrome
Conditions
Interventions
None listed
Sponsors
Chiba University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with ischemic heart disease who will undergo or have undergone percutaneous coronary intervention 2. Patients who are provided of the written agreement 3. Twenty to 85 years old
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to prasugrel 2. Patients who have severe liver problem 3. Patients who have severe kidney problem 4. Weigh 45 kg or less 5. low platelet counts (less than 10*10^4) 6. Pregnant 7. Patients who are taking anticoagulants 8. Patients who are planned to administer thrombolytic agents 9. Patients scheduled for PCI or coronary artery bypass graft during this study 10. Patients who are taking ticlopidine or cilostazol 11.Cardiogenic shock 12.History of stroke or transient ischemic attack 13. Patients judged as inappropriate for trial entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is the change of platelet reactivity unit (PRU) and inhibition rate which measured by VerifyNow P2Y12 platform assay. PRU is measured before prasugrel start, and 30 minutes, one hour, 2hours, 4hours and 6hours after prasugrel loading dose(20mg), and Prasugrel maintenance dose(3.75mg) and clopidogrel maintenance dose (75mg) | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary efficacy endpoints are the variation in the rate of high on-treatment platelet reactivity (HPR) and the average value of the change of PRU, | — |
Countries
Japan
Contacts
Public ContactShinichi Wakabayashi
Chiba University Hospital Department of Cardiovascular Medicine
Outcome results
None listed